METHAZOLAMIDE - Generic Drug Details

What are the generic sources for methazolamide and what is the scope of patent protection?

Methazolamide is the generic ingredient in two branded drugs marketed by Ani Pharms, Applied Anal, Athem, Bausch And Lomb Inc, Mikart, Sandoz, Tagi, and Lederle, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for methazolamide. Twelve suppliers are listed for this compound.

Summary for METHAZOLAMIDE

US Patents:	0
Tradenames:	2
Applicants:	8
NDAs:	8
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	117
Clinical Trials:	9
Patent Applications:	6,425
Drug Prices:	Drug price trends for METHAZOLAMIDE
What excipients (inactive ingredients) are in METHAZOLAMIDE?	METHAZOLAMIDE excipients list
DailyMed Link:	METHAZOLAMIDE at DailyMed

See drug prices for METHAZOLAMIDE

Recent Clinical Trials for METHAZOLAMIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wilderness Medical Society	Phase 4
University of Waterloo	Phase 4
University of British Columbia	Phase 4

See all METHAZOLAMIDE clinical trials

Medical Subject Heading (MeSH) Categories for METHAZOLAMIDE

Carbonic Anhydrase Inhibitors

Diuretics

Anatomical Therapeutic Chemical (ATC) Classes for METHAZOLAMIDE

S01EC	Carbonic anhydrase inhibitors
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for METHAZOLAMIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lederle	NEPTAZANE	methazolamide	TABLET;ORAL	011721-002	Nov 25, 1991		DISCN	Yes	No
Tagi	METHAZOLAMIDE	methazolamide	TABLET;ORAL	215615-002	Oct 18, 2022	AB	RX	No	No
Applied Anal	METHAZOLAMIDE	methazolamide	TABLET;ORAL	040011-002	Jul 17, 1997		DISCN	No	No
Tagi	METHAZOLAMIDE	methazolamide	TABLET;ORAL	215615-001	Oct 18, 2022	AB	RX	No	No
Athem	METHAZOLAMIDE	methazolamide	TABLET;ORAL	040102-001	Aug 28, 1996		DISCN	No	No
Ani Pharms	METHAZOLAMIDE	methazolamide	TABLET;ORAL	040001-001	Jun 30, 1993	AB	RX	No	No

METHAZOLAMIDE Market Analysis and Financial Projection Experimental

Methazolamide Market Dynamics and Financial Trajectory

Introduction to Methazolamide

Methazolamide is a carbonic anhydrase inhibitor, primarily used to treat glaucoma by reducing intraocular pressure. It is administered orally, making it a systemic therapy option for patients, particularly those who do not respond to other treatments.

Market Size and Growth Projections

The global methazolamide market has been experiencing significant growth and is projected to continue this trend. As of 2023, the market size was valued at USD 9,269.8 million, and it is estimated to reach USD 16,781.2 million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 6.9% from 2024 to 2032[2].

Market Segmentation

The methazolamide market is segmented based on several key factors:

• Type: This includes acetazolamide, methazolamide, furosemide, topiramate, and others.
• Application: The primary applications are in hospitals, clinics, and ambulatory surgery centers.
• Geography: The market is analyzed across regions such as North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa[1][2].

Regional Outlook

North America and Europe

These regions are driven by advanced healthcare infrastructure, high prevalence of glaucoma, and robust pharmaceutical industries. Extensive research and development activities, along with the presence of key pharmaceutical companies and well-established distribution networks, contribute to the market growth in these areas[2].

Asia-Pacific

This region is emerging as a significant market due to increasing healthcare expenditure, improving access to healthcare services, and rising awareness about ocular health. The large population base, aging population, and changing lifestyles further contribute to the expanding market opportunities[2].

Latin America and Middle East & Africa

These regions are experiencing gradual growth supported by improving healthcare infrastructure and increasing initiatives to combat eye diseases[2].

Market Drivers

• Increasing Prevalence of Glaucoma: With over 60 million suspected cases of glaucoma worldwide in 2023, the demand for effective treatments like methazolamide is on the rise[2].
• Aging Population: The growing elderly population, which is more prone to glaucoma and other ocular disorders, drives the market growth.
• Advances in Pharmaceutical Technologies: Enhancements in drug efficacy and the development of innovative combination therapies are boosting the market[2].

Market Restraints

• Side Effects: Methazolamide's potential side effects, such as electrolyte imbalances and blood disorders, limit its widespread adoption.
• Alternative Treatments: Competition from other medications and surgical options hinders market growth.
• High Treatment Costs: High costs can restrict patient accessibility, particularly in developing regions[2].

Competitive Landscape

The methazolamide market includes several key players such as Avkare, FDC, Heritage Pharmaceuticals Inc, Ingenus Pharmaceuticals, Janssen - Cilag Pharmaceuticals SA, Lannett Company, Medtronic, MercuryPharma, Nostrum Laboratories Inc, and Novast Holdings Ltd. These companies are profiled based on their product offerings and market-related factors, including their year of market entry[1].

Market Opportunities

• Emerging Markets: Expanding into emerging markets with improving healthcare infrastructure and increasing ocular health awareness presents significant growth opportunities.
• Innovative Therapies: Research into new therapeutic applications beyond glaucoma and the development of combination therapies could enhance treatment efficacy and patient compliance[2].

Economic and Financial Analysis

The market is subject to a thorough economic analysis, including:

• Porter's 5 Forces Framework: This framework helps in understanding the competitive landscape and the bargaining power of suppliers and buyers.
• Macroeconomic Analysis: Factors such as GDP growth, healthcare expenditure, and demographic changes are considered.
• Value Chain Analysis: This involves examining the entire supply chain from raw material procurement to end-user delivery.
• Pricing Analysis: The report delves into the pricing strategies and their impact on market dynamics[1][4].

Key Trends and Dynamics

• Glaucoma Treatment Dominance: Glaucoma treatment is the primary application driving the methazolamide market, given its high demand and prevalence worldwide.
• Oral Administration: Methazolamide's oral tablets hold the maximum share of the market due to their efficacy in reducing intraocular pressure[2].

Future Outlook

The methazolamide market is poised for significant growth, driven by increasing demand for effective glaucoma treatments and advancements in pharmaceutical technologies. However, the market must navigate challenges such as side effects, competition from alternative treatments, and high treatment costs.

"Methazolamide is extensively given as an oral drug due to its efficacy in decreasing intraocular pressure, making it an essential treatment for glaucoma sufferers." - Acumen Research and Consulting[2]

Key Takeaways

• The global methazolamide market is projected to grow at a CAGR of 6.9% from 2024 to 2032.
• The market is driven by the increasing prevalence of glaucoma and advancements in pharmaceutical technologies.
• North America and Europe are leading regions, while Asia-Pacific is emerging as a significant market.
• Side effects and high treatment costs are key restraints.
• Emerging markets and innovative therapies present growth opportunities.

FAQs

What is the projected market size of methazolamide by 2032?

The global methazolamide market is estimated to reach USD 16,781.2 million by 2032[2].

What is the primary application driving the methazolamide market?

Glaucoma treatment is the primary application driving the methazolamide market due to its high demand and prevalence worldwide[2].

Which regions are expected to dominate the methazolamide market?

North America and Europe are currently dominant regions, while Asia-Pacific is emerging as a significant market[2].

What are the key restraints in the methazolamide market?

Key restraints include potential side effects, competition from alternative treatments, and high treatment costs[2].

What opportunities are available for growth in the methazolamide market?

Expanding into emerging markets and developing innovative combination therapies present significant growth opportunities[2].

Sources:

1. Market Research Intellect - Global Methazolamide Market Size, Scope And Forecast Report[1]
2. Acumen Research and Consulting - Methazolamide Market Size, Share, Trends | Forecast 2032[2]
3. Cognitive Market Research - Global Methazolamide Market Report 2024 Edition[4]